Health-tech company Aetion — founded by Harvard Medical School faculty members to promote value-based care through a real-world analytics and evidence platform — announced today that it has received $27 million in funding from biopharma and healthcare services investors.
New backers include Sanofi, UCB, McKesson Ventures and Horizon Health Services, along with existing investors NEA, Flare Capital and Lakestar.
The investment brings the total Series B funding to $63 million. It boosts Aetion’s total funding to $77 million since its launch in 2015.
The money will be used to strengthen the Aetion Evidence Platform, which focuses on patient outcomes by using real-world data generated by the healthcare system and analyses in epidemiology to foster validated decisions. The investment could allow the platform to extend its reach in therapeutic-related intelligence and outcomes-based contracting for payers. Aetion also plans to advance the acceptance of standards for real-world evidence globally.
“We’re entering a new era in which nearly the entire healthcare ecosystem — from biopharma and regulators to payers and technology companies — recognize the importance of using real-world evidence to reduce the time and cost to bring new therapies to the market,” said Carolyn Magill, CEO of Aetion.
According to the announcement, the Aetion Evidence Platform is used by eight of the top 15 global biopharma firms, leading payers, academic institutions and the U.S. Food and Drug Administration, among others.
Aetion’s senior director, Brittany Ryan, earned a spot on MedTech Boston’s 40 Under 40 list last year for her commitment to changing the healthcare system for the better.
Ryan has previously worked for UnitedHealth Group, where she helped promote cross-stakeholder innovation within the healthcare system. She worked with pharma companies, providers and payers to design, implement and assess the value of clinical interventions in key disease areas.
Now at Aetion, Ryan is in an environment where healthcare stakeholders can push the boundaries of value and standardize the use of real-world evidence in the space.
Send this to a friend